VIVSNasdaq

VivoSim Labs, INC.

Healthcare·Immunology·Phase 2·San Diego, CA, United States
ImmunologyInfectious DiseaseMetabolic

VivoSim Labs, INC. (VIVS): 1 pipeline candidate · ~6 mo cash runway. Updated within the last hour.

5.1/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway1.8

6.4 months

Financial Health9.1

D/E 0.57 · 0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for VivoSim Labs, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$3.4M

Cash

$4.3M

Quarterly Burn

$2.3M

Runway

6.4 mo

Revenue

$26K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Dec 2026
Today~7 mo out
Catalyst within runway

Pipeline (1 candidate)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

20

Total value held

$157K

HolderSharesValue
geode capital management, llc36,850$53K
vanguard capital management llc30,742$44K
goldman sachs group inc16,072$23K
blackrock, inc.11,817$17K
vanguard fiduciary trust co7,003$10K
citigroup inc6,504$9K
larson financial group llc166$237
albion financial group /ut159$228
wells fargo & company/mn111$158
osaic holdings, inc.95$131

Showing top 10 of 20 institutional holders of VivoSim Labs, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Douglas Jay Cohen

Frequently asked questions

How many drug candidates are in VivoSim Labs, INC.'s pipeline?

VivoSim Labs, INC. (VIVS) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is VivoSim Labs, INC.'s lead drug candidate?

VivoSim Labs, INC.'s most advanced tracked candidate is fxr314 (Phase 2) for Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD); metabolic function-associated steatohepatitis (MASH).

What is VivoSim Labs, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, VivoSim Labs, INC. has approximately 6.4 months of cash runway.

What is VivoSim Labs, INC.'s market capitalization?

VivoSim Labs, INC.'s market capitalization is approximately $3.4M.

Who is the CEO of VivoSim Labs, INC.?

Douglas Jay Cohen is the chief executive officer of VivoSim Labs, INC. (VIVS).

Get the full picture on VivoSim Labs, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.